

# Ashwin A Patkar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7412442/publications.pdf>

Version: 2024-02-01

77  
papers

1,850  
citations

279487

23  
h-index

288905

40  
g-index

82  
all docs

82  
docs citations

82  
times ranked

2722  
citing authors

#	ARTICLE	IF	CITATIONS
1	Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam Medical Journal, 2018, 54, 101.	0.5	181
2	A Randomized, Double-blind, Placebo-controlled Trial of Augmentation With an Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression. Journal of Clinical Psychopharmacology, 2006, 26, 653-656.	0.7	106
3	Psychometric Properties of the Patient Health Questionnaire-15 (PHQ-15) for Measuring the Somatic Symptoms of Psychiatric Outpatients. Psychosomatics, 2009, 50, 580-585.	2.5	88
4	A Randomized, Controlled, Trial of Controlled Release Paroxetine in Fibromyalgia. American Journal of Medicine, 2007, 120, 448-454.	0.6	81
5	A review of current evidence for acetyl-L-carnitine in the treatment of depression. Journal of Psychiatric Research, 2014, 53, 30-37.	1.5	80
6	Aripiprazole as Adjunctive Therapy for Patients with Major Depressive Disorder. CNS Drugs, 2011, 25, 109-127.	2.7	79
7	Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study. Psychopharmacology, 2009, 206, 479-489.	1.5	70
8	Aripiprazole in the Treatment of Depressive and Anxiety Disorders. CNS Drugs, 2008, 22, 367-388.	2.7	66
9	Transdermal Selegiline: <i>The New Generation of Monoamine Oxidase Inhibitors</i>. CNS Spectrums, 2006, 11, 363-375.	0.7	64
10	A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State. PLoS ONE, 2012, 7, e34757.	1.1	56
11	Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Medical Journal, 2016, 52, 159.	0.5	48
12	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis. Journal of Psychiatric Research, 2015, 64, 88-98.	1.5	47
13	Atypical Antipsychotic Augmentation Strategies in the Context of Guideline-based Care for the Treatment of Major Depressive Disorder. CNS Drugs, 2013, 27, 29-37.	2.7	44
14	An Open-Label, Rater-Blinded, Augmentation Study of Aripiprazole in Treatment-Resistant Depression. Primary Care Companion To the Journal of Clinical Psychiatry, 2006, 8, 82-7.	0.6	43
15	Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. Journal of Psychiatric Research, 2017, 84, 292-300.	1.5	37
16	Changes in Tobacco Smoking Following Treatment for Cocaine Dependence. American Journal of Drug and Alcohol Abuse, 2006, 32, 135-148.	1.1	35
17	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clinical Psychopharmacology and Neuroscience, 2018, 16, 469-480.	0.9	35
18	Vilazodone for the Treatment of Depression: An Update. Chonnam Medical Journal, 2016, 52, 91.	0.5	34

#	ARTICLE	IF	CITATIONS
19	Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis. <i>Journal of Psychiatric Research</i> , 2020, 125, 164-176.	1.5	33
20	The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. <i>Journal of Psychiatric Research</i> , 2014, 56, 72-81.	1.5	27
21	Genome-Wide Meta-Analysis of Longitudinal Alcohol Consumption Across Youth and Early Adulthood. <i>Twin Research and Human Genetics</i> , 2015, 18, 335-347.	0.3	26
22	Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action. <i>Psychiatry Investigation</i> , 2015, 12, 155.	0.7	26
23	Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients. <i>Psychopharmacology</i> , 2006, 185, 123-132.	1.5	25
24	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. <i>BMC Psychiatry</i> , 2016, 16, 106.	1.1	24
25	A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. <i>Hepatology</i> , 2020, 71, 1894-1909.	3.6	24
26	Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1. <i>Neuropsychobiology</i> , 2016, 74, 159-168.	0.9	23
27	Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol-abusing individuals. <i>Addiction Biology</i> , 2005, 10, 261-268.	1.4	22
28	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 235-248.	0.9	19
29	Clinical Issues in Use of Atypical Antipsychotics for Depressed Patients. <i>CNS Drugs</i> , 2013, 27, 39-45.	2.7	18
30	Investigational dopamine antagonists for the treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 687-698.	1.9	18
31	Efficacy of antidepressants: bias in randomized clinical trials and related issues. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 15-25.	1.3	16
32	Investigation of an epistatic effect between a set of TAAR6 and HSPA670 genes variations and major mood disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 680-683.	1.1	15
33	Precision medicine for psychopharmacology: a general introduction. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 831-839.	1.4	15
34	Characteristics of neurocognitive functions in mild cognitive impairment with depression. <i>International Psychogeriatrics</i> , 2016, 28, 1181-1190.	0.6	15
35	The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. <i>Advances in Therapy</i> , 2017, 34, 713-724.	1.3	15
36	Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017, 15, 28-34.	0.9	15

#	ARTICLE	IF	CITATIONS
37	Increased plasma complement factor H is associated with geriatric depression. <i>International Psychogeriatrics</i> , 2019, 31, 101-108.	0.6	15
38	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. <i>Advances in Therapy</i> , 2018, 35, 1656-1670.	1.3	14
39	Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD). <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	13
40	Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder. <i>Psychiatry Investigation</i> , 2014, 11, 481.	0.7	13
41	Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1541-1552.	1.4	12
42	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. <i>Journal of Affective Disorders</i> , 2019, 249, 410-417.	2.0	12
43	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for <i>CACNA1C</i> , <i>CHRNA7</i> and <i>MAPK1</i> . <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 364-368.	0.9	12
44	The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 495-502.	0.9	12
45	Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials. <i>CNS Spectrums</i> , 2014, 19, 324-329.	0.7	11
46	A 13-Week, Randomized Double-Blind, Placebo-Controlled, Cross-Over Trial of Ziprasidone in Bipolar Spectrum Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 319-323.	0.7	11
47	A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders. <i>PLoS ONE</i> , 2017, 12, e0179247.	1.1	10
48	Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 153-158.	0.9	9
49	Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1605.	1.0	8
50	Aripiprazole augmentation for major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 116-119.	0.9	8
51	Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. <i>CNS Spectrums</i> , 2018, 23, 402-413.	0.7	8
52	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 901-910.	1.8	8
53	The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2018, 72, 73-85.	0.8	7
54	Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 434-448.	0.9	7

#	ARTICLE	IF	CITATIONS
55	An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder. <i>primary care companion for CNS disorders, The</i> , 2015, 17, .	0.2	7
56	Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. <i>Journal of Psychiatric Research</i> , 2008, 42, 1213-1219.	1.5	6
57	Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 600-609.	0.9	6
58	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 273-286.	1.1	5
59	<i>ZNF804A</i> Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 231-240.	0.9	5
60	Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study. <i>Psychiatry Investigation</i> , 2022, 19, 268-280.	0.7	5
61	Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. <i>Human Psychopharmacology</i> , 2006, 21, 367-375.	0.7	4
62	Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 243-253.	0.9	4
63	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. <i>Advances in Therapy</i> , 2017, 34, 1482-1497.	1.3	3
64	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 62-74.	1.1	3
65	Updates on Preclinical and Translational Neuroscience of Mood Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 665-672.	0.7	3
66	Effects of Milnacipran on Neurocognition, Pain, and Fatigue in Fibromyalgia. <i>primary care companion for CNS disorders, The</i> , 2013, 15, .	0.2	3
67	A Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study of Milnacipran for Chronic Radicular Pain (Sciatica) Associated With Lumbosacral Disc Disease. <i>primary care companion for CNS disorders, The</i> , 2014, 16, .	0.2	3
68	Transdermal selegiline. <i>Drugs of Today</i> , 2007, 43, 361.	0.7	3
69	Sickness absence indicating depressive symptoms of working population in South Korea. <i>Journal of Affective Disorders</i> , 2018, 227, 443-449.	2.0	2
70	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 46-52.	0.9	2
71	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. <i>Psychiatry Investigation</i> , 2014, 11, 200.	0.7	2
72	Attitudes on clinical research participation of community living elders in <sc>K</sc>orea. <i>Asia-Pacific Psychiatry</i> , 2012, 4, 168-173.	1.2	1

#	ARTICLE	IF	CITATIONS
73	Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 233-242.	0.9	1
74	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018, 16, 469-480.	0.9	1
75	Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study. <i>Current Therapeutic Research</i> , 2008, 69, 221-231.	0.5	0
76	Corrigendum to: "TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study" [Eur Psychiatr 2008;23:390-5]. <i>European Psychiatry</i> , 2009, 24, 64-64.	0.1	0
77	PM449. Hot genes in schizophrenia: case-control, pharmacogenetics and exploratory analyses in two independent samples. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, 63-63.	1.0	0